Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more – STAT
Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more STATIn surprise decision, FDA rejects radiopharma therapy…
Pharmalittle: Sanofi experiencing drug shortages, Jazz buying Actio
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating…
How rising oil prices can boost the cost of some medicines
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
AI scribes: Useful tools in medical education or a crutch that imperils learning?
Lauren writes about healthcare AI data interoperability, the science behind public health recommendations, and pharmaceutical advances in the…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Medicare eliminates key pathways used by ‘breakthrough’ devices for extra payments
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
Pharmalittle: Novo discloses setback, Replimune drug endorsed
And so, another working week will soon come to a close. Not a moment too soon, yes? This…
Can doctors trust clinical AI? The complicated issue of LLM benchmarks
Katie covers the impact of health technology on patients, clinicians, and businesses. Her stories explore the price tag…
Pharmalittle: FDA panel nixed Duchenne drug, Hims & Hers sued| STAT
Top of the morning to you, and a fine one it is. Skies are gray but rain is…
Pharmalittle: FDA panel backs pharmacies to make peptides
And so, another working week will soon draw to a close. Not a moment too soon, yes? This…
FDA is urged by advocacy group to ban DTC prescription drug ads
Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He…
Barriers may keep Merck’s new cholesterol drug from success
A long-awaited moment in preventive cardiology arrived last week, when enlicitide (which Merck is selling under the name…